[Cutaneous plasmacytomas following treatment of IgA kappa multiple myeloma].
Ortín
Xavier
X
Llorente
Andreu
A
Martínez
Salomé
S
Ugarriza
Aránzazu
A
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology*; D007145:Immunoglobulin kappa-Chains / Q000276:immunology*; D008297:Male; D008558:Melphalan / Q000009:adverse effects* / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology*; D010954:Plasmacytoma / Q000139:chemically induced*; D011239:Prednisolone / Q000009:adverse effects* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000139:chemically induced*
D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; D007070:Immunoglobulin A; D007145:Immunoglobulin kappa-Chains; D011239:Prednisolone; D008558:Melphalan